EUVIMEDEUVIMED entdecken
Crossref

PDK1‐stabilized LncRNA SPRY4‐IT1 promotes breast cancer progression via activating NF‐κB signaling pathway

Yulu Zhang, Hongling Chen, Renjie Yuan, Yange Wang, Dian Zhang, Qian Zeng, Weiqian Jiang, Ruiming Zhang, Tingmei Chen, Chengsen Chai, Bianqin Guo

Molecular Carcinogenesis · 2023

DOI: 10.1002/mc.23542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2023. Verfasst von Yulu Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, C…. Hauptthemen laut MEDLINE: Breast Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pyruvate dehydrogenase kinase 1 (PDK1) is a widely known glycolytic enzyme, and some evidence showed that PDK1 promoted breast cancer by multiple approaches. However, very few lncRNAs have been identified to be associated with PDK1 in breast cancer in previous research. In this study, we found that lncRNA sprouty4‐intron transcript 1 (SPRY4‐IT1) was regulated by PDK1 with correlation analysis, and PDK1 upregulated SPRY4‐IT1 remarkably in breast cancer cells, as PDK1 interacted with SPRY4‐IT1 in the nucleus and significantly enhanced the stability of SRPY4‐IT1. Furthermore, SPRY4‐IT1 was highly expressed in breast cancer, significantly promoted the proliferation and inhibited apoptosis of breast cancer cells. In terms of mechanism, SPRY4‐IT1 inhibited the transcription of NFKBIA and the expression of IκBα, thus promoting the formation of p50/p65 complex and activating NF‐κB signaling pathway, which facilitated survival of breast cancer cells. Therefore, our finding reveals that PDK1/SPRY4‐IT1/ NFKBIA axis plays a crucial role that promoting tumor progression, and SPRY4‐IT1 knockdown incombined with PDK1 inhibitor is promising to be a new therapeutic strategy in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRNA, Long NoncodingHumansFemaleNF-kappa BCell Line, TumorIntronsCell ProliferationSignal TransductionGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

NF-κB signaling pathwayPDK1SPRY4-IT1breast cancer

Substanzen

RNA, Long NoncodingNF-kappa B

Autor:innen und Institutionen

  • Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, China.
  • Department of Orthopedics, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Clinical Laboratory, Chongqing University Cancer Hospital, Chongqing, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y., Chen, H., Yuan, R., Wang, Y., Zhang, D., Zeng, Q., Jiang, W., Zhang, R., Chen, T., Chai, C., & Guo, B. (2023). PDK1‐stabilized LncRNA SPRY4‐IT1 promotes breast cancer progression via activating NF‐κB signaling pathway. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23542

Vancouver

Zhang Y, Chen H, Yuan R, Wang Y, Zhang D, Zeng Q, et al. PDK1‐stabilized LncRNA SPRY4‐IT1 promotes breast cancer progression via activating NF‐κB signaling pathway. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23542

BibTeX
@article{Zhang2023,
  author = {Zhang, Yulu and Chen, Hongling and Yuan, Renjie and Wang, Yange and Zhang, Dian and Zeng, Qian and Jiang, Weiqian and Zhang, Ruiming and Chen, Tingmei and Chai, Chengsen and Guo, Bianqin},
  title = {PDK1‐stabilized LncRNA SPRY4‐IT1 promotes breast cancer progression via activating NF‐κB signaling pathway},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  doi = {10.1002/mc.23542}
}
Kostenlos starten →